


# Respiratory Syncytial Virus Mother and Infant Protection Program (RSV- MIPP) 2025

## Nirsevimab decision aid – newborn infants

### Decision aid to determine if a newborn infant is eligible to receive nirsevimab under the Victorian RSV-MIPP 2025

Refer to the [Australian Immunisation Handbook - RSV Chapter](https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv) for further details <https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/respiratory-syncytial-virus-rsv>.



For further clinical advice, please contact the Victorian immunisation hotline – 1300 882 924:

- **Option 2:** Royal Children’s Hospital Immunisation Centre, including telehealth
- **Option 5:** Monash Health Immunisation Service, including telehealth

To report significant or unexpected side effects following immunisation (AEFI, including vaccine error), contact SAEFVIC, the central reporting service for Victoria:

- Online: [SAEFVIC](https://www.saefvic.org.au/) <https://www.saefvic.org.au/>, 24 hours a day, 7 days a week
- Phone: 1300 882 924, option 1. Hours of operation are Monday – Friday 10.00am–2.00pm (except public holidays)
- Email: [enquiries@saefvic.org.au](mailto:enquiries@saefvic.org.au)



Department  
of Health

To receive this document in another format, email the Immunisation Program: [immunisation@health.vic.gov.au](mailto:immunisation@health.vic.gov.au).

Authorised and published by the Victorian Government, 1 Treasury Place, Melbourne.  
© State of Victoria, Australia, Department of Health, March 2025. (2503100)